Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Immuron
February 19, 2021
Immunome soars 76% on Covid-19 hopes – but that's nothing
June 12, 2018
Investors toast Galmed Nash results, but what will the FDA say?
February 13, 2017
Intercept strikes at the heart of the Nash problem
July 25, 2016
Despite a deck stacked in its favour, Tobira fails in NASH
May 03, 2016
Therapy focus – NASH projects set for data in dog days of summer
September 24, 2015
Conatus makes a splash in NASH
April 08, 2015
Astra first big pharma to dip toe in simmering NASH waters
March 10, 2015
NASH craze lives on, despite the unknowns
August 09, 2013
Sanofi brings prospect of C difficile vaccine closer
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
November 10, 2022
Pharma Market Drivers Part Three: Blowin’ in the wind
November 02, 2022
Q3 Round Up: Alive but not kicking report
Editor's Picks
September 28, 2022
Lecanemab can; now the wait for details begins
October 10, 2022
The gloom deepens for biopharma stocks
October 06, 2022
SITC 2022 preview – cytokines and oral checkpoints
September 27, 2022
Big pharma’s key fourth-quarter data
September 21, 2022
TCT 2022 – Otsuka’s renal denervation system shines
